Pure Global AI
NCT06327698Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Efficacy and Safety of Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure: A Single-arm, Open-label, Multicenter Phase II Clinical Study
Hunan Cancer HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
Cadonilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hunan Cancer Hospital
Timeline & enrollment
Phase
Phase 2
Start date
May 15, 2024
End date
May 31, 2027
Enrollment
30 participants
Primary outcome

Response Rate

Summary

This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the
 effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of
 locally advanced or metastatic melanoma.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06327698
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06327698 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Cancer Hospital and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.